Norinchukin Bank The Boosts Holdings in Becton, Dickinson and Company $BDX

Key Points

• Norinchukin Bank increased its stake in Becton, Dickinson and Company by 12.2%, owning a total of 12,687 shares valued at approximately $2.9 million as of its latest SEC filing.
• Multiple hedge funds have shown interest in Becton, Dickinson, with institutional investors now holding 86.97% of the company's stock.
• Wall Street analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average price target of $211.44, though recent reports have shifted ratings between "Buy" and "Hold."

Norinchukin Bank The lifted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 12.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,687 shares of the medical instruments supplier's stock after purchasing an additional 1,380 shares during the quarter. Norinchukin Bank The's holdings in Becton, Dickinson and Company were worth $2,906,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of BDX. Smallwood Wealth Investment Management LLC purchased a new position in Becton, Dickinson and Company in the 1st quarter worth about $27,000. REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 55 shares during the last quarter. Alpine Bank Wealth Management purchased a new position in Becton, Dickinson and Company in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC raised its position in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 99 shares during the last quarter. Finally, Nexus Investment Management ULC purchased a new position in Becton, Dickinson and Company in the 1st quarter worth about $34,000. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a research report on Friday, May 2nd. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their price target for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $211.44.

Becton, Dickinson and Company Trading Down 1.4%

BDX opened at $196.4380 on Friday. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a market cap of $56.31 billion, a P/E ratio of 35.33, a PEG ratio of 1.49 and a beta of 0.20. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The business's 50-day simple moving average is $180.10 and its 200-day simple moving average is $195.89.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the prior year, the business posted $3.50 EPS. The business's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Insider Activity

In related news, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This represents a 20.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,214 shares of company stock worth $579,206. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.